Background and Objective:Selective internal radiation therapy(SIRT)represents an endovascular treatment option for patients with hepatocellular carcinoma(HCC).Its use is widely recognized in the intermediate and advan...
Background:This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma(FLC)treated with liver-directed therapies(LDT).Methods:In this single-center retrospective study,all pat...
As the third leading cause of cancer-related deaths worldwide,hepatocellular carcinoma(HCC)represents a significant global health challenge.This paper provides an introduction and comprehensive review of transarterial...
Project of City-University Science and Technology Strategic Cooperation of Nanchong City,No.20SXQT0324。
With continuous advancements in interventional radiology,considerable progress has been made in transarterial therapies for hepatocellular carcinoma(HCC)in recent years,and an increasing number of research papers on t...
Immunotherapy and the implementation of more aggressive treatment schemes for locally advanced hepatocellular carcinomas have expanded the boundaries of curative options.Because of these advancements,patients who were...
In this editorial,we review the article by Ma and colleagues,published in the World Journal of Gastrointestinal Oncology.Hepatocellular carcinoma(HCC)is a major cause of cancer-related mortality.Although transarterial...
Transarterial radioembolization or selective internal radiation therapy(SIRT)has emerged as a minimally invasive approach for the treatment of tumors.This percutaneous technique involves the local,intra-arterial deliv...
We read with interest this article evaluating the results of transarterial radioembolization(TARE)in the management of large(≥5 cm)initially unresectable hepatocellular carcinoma(HCC)(1).The aim of this retrospective...
Liver malignancy,including primary liver cancer and metastatic liver cancer has become one of the most common causes of cancer-related death worldwide due to the high malignant degree and limited systematic treatment ...
Purpose:The IMbrave150 PhaseⅢtrial demonstrated superiority of atezolizumab and bevacizumab(Atezo/Bev)over sorafenib for unresectable hepatocellular carcinoma(HCC).The present study aims to evaluate the feasibility o...